SPOTLIGHT -
Novel CAR T Utility Must Be Confirmed Across Hematologic Malignancies
FDA Approval Insights: Zanubrutinib in CLL and SLL
Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium
Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
EP0042 Wins FDA Orphan Drug Status for Acute Myeloid Leukemia
FDA Approves Nelarabine Injection for T-cell Leukemia and Lymphoma
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
